This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Cancer Diagnostics Market

Market Insights on Cancer Diagnostics covering sales outlook, demand forecast & up-to-date key trends

Cancer Diagnostics Market by Test Type (Tumour Biomarkers Tests, Imaging, Biopsy, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization), End-user & Region - Forecast to 2021-2031

Cancer Diagnostics Market - About the Report

[285 Pages Report] The rising prevalence of cancers has necessitated innovation in the cancer diagnostics. The global market is set to grow at an impressive pace over forecast period. Use of advanced technologies such as liquid biopsy for breast cancer, prostate cancer and lung cancer diagnosis and treatment can result in favorable therapeutic outcomes. Furthermore, the increasing advancements in imaging technologies for early-stage diagnosis of cancer is expected to boost the market for cancer diagnostics.

In its latest edition of the study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights about key factors driving demand for cancer diagnostics. The report tracks the global sales of cancer diagnostics in 20+ high-growth markets, along with analyzing the impact COVID-19 has had on cancer diagnosis services in general, and cancer diagnostics in particular.

Customize this Report

Let us know your requirement to get
100% FREE customization

How Historical and Future Outlook for Cancer Diagnostics Market Match Up?

As per the World Health Organization (WHO), in 2020 around 19 Mn new cancer cases were diagnosed across the world. Likewise, the American Cancer Society reported that the 89,500 cases of cancer were diagnosed in U.S. in 2020. The most common cancers in the U.S. include lung cancer, breast cancer, prostate cancer, colorectal cancer, thyroid cancer, pancreatic cancer, non-Hodgkin lymphoma, melanoma, endometrial cancer, renal pelvis cancer, kidney cancer and leukemia.

Governments in developed countries such as the U.S. raise funds for cancer research to aid in the diagnosis and treatment. They also are funding clinical trials to support companies in developing effective diagnostic tests for cancer. According to the American Association for Cancer Research, Cancer Epidemiology, Biomarkers & Prevention journal reported that national cancer-attributable costs in the United States are projected to increase by over 30 % from 2015 to 2030, corresponding to a total cost of over $245 billion.

Late diagnosis of cancer is the chief reason behind the rising mortality rates. This has been fuelling the demand for improvement in screening and diagnosis. Moreover, investments in the field of research is estimated to create new opportunities for the cancer diagnostics market in the coming years. Research funding from governments and improving reimbursement facilities for cancer diagnostics are expected to boost the market.

In 2019, the American Cancer Society has funded more than $67 million in breast cancer research through 162 research and training grants. Likewise, the increased funding for the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) by the American Cancer Society Cancer Action Network (ACS CAN), at the state and federal levels.

Similarly constantly evolving technology such as next-generation sequencing techniques for cancer diagnostics and patient-based cancer diagnostics would fuel the demand for cancer diagnostics. Next-generation sequencing (NGS) is the most cost-effective, time-saving and successful technological advances in cancer diagnostics in the last 3 decades. Revolutionary second-generation and third platforms offered by Roche, Illumina and Life Technologies, Pacific Biosciences of California, Inc. are rapidly gaining absorbed in the market. Many molecular pathology laboratories are transitioning from single molecular PCR protocols to adopt NGS platforms, and thus the market for cancer diagnostic is expected to gain traction.

Cancer Diagnostics Market Download Report Brochure

According to FMI’s analysis, cancer diagnostics sales have grown at an 8.5% CAGR between 2021 and 2031. The cancer diagnostics market experienced a short-term negative impact owing to a sharp reduction in the number of patients in hospitals for cancer diagnosis across the world. The market is expected to recover by mid-2021. As the COVID-19 cases were rising, the healthcare system had shifted its focus towards mitigating the ongoing global medical emergency.

The screening of cancer, case identification, and referral in symptomatic cancer diagnosis is declined due to the outbreak of COVID-19. Even the follow-up and management of cancer patients are also exaggerated by the pandemic. For instance, a 40% decline in weekly cancer incidence is reported by Netherlands Cancer Registry in 2020, and the U.K. has accomplished a 75% decline in referrals for assumed cancer since the onset of COVID-19.? However, in the coming years, a significant increase is projected in cancer diagnostic procedures.

FMI expects the global cancer diagnostics market to grow at 8.5% CAGR through 2031.

How is Shift towards Advanced Diagnostics Fuelling Cancer Diagnostics Demand?

Advances in diagnostics such as imaging techniques have increased the demand for cancer diagnostics. Imaging has become an important aspect of cancer detection and diagnosis and recent progress in tumour imaging technologies have improved the diagnosis of 5 common cancers including cancers of breast, lung, prostate and colorectal cancers. For instance, in 2018 ultrasound technology MicroPure was introduced by Toshiba Medical Systems Corporation for the early detection of microcalcification in breast tissue. With the growing preferences for PET cameras, the technology has gone through several evolutions resulting in cutting down the time for image processing. Similarly, the addition of PET/CT enabled the acquisition of morphological and functional information simultaneously.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What Are The Opportunities In The Cancer Diagnostics Market?

Increasing patient acceptance for non-invasive tests & hospital laboratory needs presents huge growth opportunities for developers and manufacturers of cancer diagnostic tests. Due to healthcare cost containment in the majority of mature markets, hospital-based laboratories are facing pressure to supply more services at a reduced cost. Healthcare facilities are faced with challenges related to increasing ageing population and a rising prevalence of chronic diseases.

By 2018, almost 10% of the global population will be 65 & above. Also, global healthcare spending is expected to witness a 5.2% growth every year till 2018. This imposes cost management pressure on diagnostic labs. Thus, a majority of laboratories have started adapting informatics solutions which helps them to increase overall productivity with existing resources. In line with this, manufacturers of diagnostic tests can grab the opportunity to provide complementary services and support.

For instance, in 2016 Abbott laboratories launched AlinIQ support and services to help their laboratory partners accomplish maximize output and capacity during operations. Similarly, bioMérieux’s LEAN lab assessment program is witnessing to increase labs’ productivity by up to 30%. There is a growing concern in the development of newer and sensitive techniques to diagnose cancer patients as early as possible, especially in high-risk groups where conventional technology falls short, thus creating opportunities in the cancer diagnostics market.

What is the Potential of Imaging Technique?

Imaging helps in the better staging of cancer, along with prognostic and treatment monitoring capabilities of functional and metabolic information. Owing to these benefits, the application of imaging techniques has fundamentally increased in cancer screening programs. The adoption of advanced imaging tests such as multiphoton microscopy and magnetic resonance imaging is growing across the world.

This technology shortens acquisition time and fusion imaging by providing precise attenuation modification, and, leading to an increase in diagnostic specificity and sensitivity imaging, thus plays an important role in staging, initial diagnosis, and monitoring of treatment response. Implementation of diagnostic imaging processes will be supplementary reorganized by multimodality imaging techniques, due to their use in the improvement of a specific treatment plan for custom-made cancer treatment.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

What Is The Regulatory Impact On Cancer Diagnostics?

Insufficient insurance coverage for costly cancer diagnostics tests is the major factor hampering the growth of the global cancer diagnostics market. Despite high-value propositions of molecular diagnostics for cancer, insufficient coverage for costly test procedures discourage a large section of patients from pursuing these tests.

Furthermore, as per the new pricing policy for 2017, CMS has increased rates for numerous new CPT codes including next-generation sequencing and multi-analyte algorithm assays. For instance, CMS increased the cost of next-generation sequencing tests for genetic breast cancer (CPT code 81432) from US$ 623 to US$ 925. It is expected that state Medicaid programs will also adjust their prices to reflect Medicare rates. Regulators of CMS, as well as private payers, are progressively highlighting the growing value and single-source tests having strong evidence of clinical utility.

Development of analytical instruments used for laboratory analysis of cancer specimen and high-end instruments such as MRI, PET, SPECT equipment and next-generation sequencing platforms requires high investment in terms of both money and time. While this might discourage smaller players, some of the big pharmaceutical companies are entering into the diagnostics business.

If at all the company develops innovative diagnostic testing, they still have to invest in special clinical efficacy studies, and there is no assurance that the product will get coverage. This might create obstacles to growth.

What Are Key Trends In Cancer Diagnostics Market?

An increasing number of the key players in the cancer diagnostics market are implementing inert growth strategies to sustain in the growing competitive burden. Companies in the global market are enthusiastically involved in mergers and acquisitions, as the industry is in its growth phase as of continuous technology upgrades and the launch of novel blood tests to detect cancer.

Players in the liquid biopsy industry have started taking strategic decisions to occupy in strategic partnerships and collaborations to support their product portfolio and surge their brand share in the market. Thus, these companies have strengthened their positions in the cancer diagnostics market.

For instance, in March 2021, Agilent Technologies Inc. acquired Resolution Bioscience, to reinforce its headship position in cancer diagnostics and in September 2020, Illumina, Inc. acquired GRAIL to launch a new phase of a cancer diagnosis. This acquisition is aimed to accelerate the adoption and commercialization of transformative multi-cancer diagnosis test with the prospective to detect more cancers earlier and enable better outcomes.

Cancer Diagnostics Market - Country-wise Insights

Why is Demand for Cancer Diagnostics High in the U.S.?

The rising prevalence of cancer in the U.S. is likely to boost cancer diagnostics demand. Cancer is the second-leading cause of death in the United States. In 2020, there will be approximately 89,500 cancer cases diagnosed and around 9,300 cancer deaths in adolescents and young adults (AYAs) aged 15 to 39 years, in the US.

Moreover, the U.S. is considered the largest market for medical devices in the world, which invariably makes it a lucrative pocket for cancer diagnostics. According to SelectUSA, the medical devices market in the U.S. accounted for 40% of the global market in 2017. By 2023, it is expected to reach US$ 203 billion in valuation.

Favorable healthcare policies, coupled with high per capita healthcare spending, has created a conducive environment for the adoption of advanced cancer diagnostic technologies such as imaging in the U.S. Also, the presence of leading players is supporting growth in the U.S. Strategies undertaken by these companies include product launches and expansion plans, which will continue aiding overall expansion in the U.S.

What Are the Factors Hampering Cancer Diagnostics in South Africa?

Lack of awareness about advance cancer screening tests and insufficient treatment options leads to increasing incidence of cancer. Due to limited campaigning about the assessment of these cancers, there seems to occur minimum practice of this cancer diagnosis tests in hospitals in South Africa.  Additionally, inadequate healthcare services in South Africa as compared to the developed countries is hindering the growth of the cancer diagnostics market in South Africa.

Other factors responsible for the hindrance of cancer diagnostics services in South Africa are a financial burden, governments fail to provide proper screening and diagnosis for cancer patients and are unable to facilitate campaigns to create awareness among the population, which may impact the adoption of cancer diagnostics in this region. The market in South Africa is expected to witness sluggish growth with a revenue share of around 22% at the end of 2031.

What Is Driving Adoption Of Cancer Diagnostics In China?

Growth in East Asia is expected to happen at a faster speed. The World Health Organization has reported that in 2020, about 4.5 Mn new cancer cases are diagnosed in China. The incidence rate of obesity and hormonal exposure-related cancers, like breast cancer in females and “lifestyle change-related cancer”, such as prostate cancer in males, showed a rising trend in China which results in surging adoption of cancer diagnostics in China.

Based on results revealed in the Global Burden of Disease Study, cancer is the leading cause of death in the country in 2020. These figures are indicative of opportunities for wider penetration in China, consequently in South Asia. An increase in the incidences of cancer and increasing awareness related to early detection of cancer in Asian countries such as China is another key factor driving rapid growth in the market.

Cancer Diagnostics Market - Category-wise Insights

Why is Demand for Liquid Biopsy High?

Liquid biopsies are developing as a promising alternative to conventional biopsies, due to their noninvasiveness for the diagnosis and monitoring of cancers. Current technological advances in the liquid biopsy potential to address the current limitations of biopsies and increase the sensitivity of cancer diagnosis are results in the highest revenue in the cancer diagnostics market.

Which is the Key Indication for Cancer Diagnostics?

In terms of indication, cancer diagnostics is being resorted primarily for lung cancer diagnosis. According to the American Lung Association, approximately 541,000 Americans are living with lung cancer. According to the World Health Organization, lung cancer has caused nearly 2.21 million deaths in 2020. With the incidence of the ailment projected to increase, the demand for accurate and timely diagnosis is expected to rise.

Who is the Leading End User?

Hospital associated labs have emerged as the leading end user. Besides the higher footfall of patients, access to advanced infrastructure and modern medical tools support expansion of the segment.

Cancer Diagnostics Market - Competitive Landscape

Most of the medical device companies are currently focusing on developing advanced diagnostic tests for assessment of cancer screening.

For example, in December 2020, Philips has introduced its latest advancements in digital pathology to boosts digital pathology with enhanced informatics to advance precision diagnosis in cancer diagnosis.

Moreover, the manufactures are focusing on getting stamp of approvals for their product and also entering into partnership and collaboration agreement to expand their product portfolio in different countries globally.

For instance, in February 2021, Agilent Technologies Inc. has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx assay for expanded use in patients with non-small cell lung cancer (NSCLC).

Some of the leading companies operating in the market are:

  • Abbott Laboratories
  • Roche
  • Thermo Fisher Scientific Inc.
  • Siemens AG
  • Bio Rad Laboratories Inc.
  • Illumina, Inc. 
  • Koninklijke Philips N.V.
  • Canon Medical Systems Corporation
  • Agilent Technologies Inc.

*The list is not exhaustive, and only for representational purposes. Full competitive intelligence with SWOT analysis available in the report.

Cancer Diagnostics Market - Scope of the Report

Attribute

Details

Cancer Diagnostics Market Forecast Period

2021-2031

Cancer Diagnostics Market - Historical Data Available for

2016-2020

Cancer Diagnostics Market - Market Analysis

USD Million for Value

Cancer Diagnostics Market- Key Regions Covered

North America, Latin America, Europe, East Asia, South Asia, Oceania Middle East & Africa

Cancer Diagnostics Market - Key Countries Covered

US, Canada, Germany, U.K., France, Italy, Spain, Poland, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, South Africa

Cancer Diagnostics Market - Key Segments Covered

Test Type, Indication, End-user and Region

Key Companies Profiled
  • Abbott Laboratories
  • Roche
  • Thermo Fisher Scientific Inc.
  • Siemens AG
  • Bio Rad Laboratories Inc.
  • Illumina, Inc.
  • Koninklijke Philips N.V.
  • Canon Medical Systems Corporation
  • Agilent Technologies Inc.

Cancer Diagnostics Market- Report Coverage

Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Cancer Diagnostics Market by Category

Test Type

  • Tumour Biomarkers Tests
    • PSA Tests
    • CTC Tests
    • AFP Tests
    • CA Tests
    • HER2 Tests
    • BRCA Tests
    • ALK Tests
    • CEA Tests
    • EGFR Mutation Tests
    • KRAS Mutation Tests
    • Others
  • Imaging
    • Ultrasound
    • Mammography
    • MRI Scan
    • PET Scan
    • CT Scan
    • SPECT & Others
  • Biopsy
    • Needle Biopsy
    • Endoscopic Biopsy
    • Bone Marrow Biopsy
    • Others
  • Liquid Biopsy
  • Immunohistochemistry
  • In Situ Hybridization

Indication

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Melanoma
  • Blood Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • Stomach Cancer
  • Liver Cancer
  • Others

End-user

  • Hospital Associated Labs
  • Independent Diagnostic Laboratories
  • Diagnostic Imaging Centers
  • Cancer Research Institutes
  • Others

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East and Africa (MEA)

Frequently Asked Questions

The US currently leads the North America market for cancer diagnostics. Sales in the US will account for over 85% of total demand in North America throughout the forecast period.

Liquid Biopsy is in high demand in terms of test type. This is because of its ease of operability and noninvasiveness.

Hospitals associated labs have emerged as leading the end user in the cancer diagnostics market.

Some of the leading players operating in the cancer diagnostics market are Abbott Laboratories, Roche, Thermo Fisher Scientific Inc., Siemens AG, Bio Rad Laboratories Inc., Illumina, Inc., Koninklijke Philips N.V., Canon Medical Systems Corporation, and Agilent Technologies Inc. among others

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Market Dynamics

    2.4. Inclusions and Exclusions

3. Market Background

    3.1. Macro-Economic Factors

        3.1.1. Global GDP Growth Outlook

        3.1.2. Global Healthcare Expenditure Outlook

        3.1.3. Growth of Healthcare Sector in Emerging Nations

    3.2. Forecast Factors - Relevance & Impact

        3.2.1. Global Increase in Healthcare Expenditure

        3.2.2. Rising Prevalence of Cancer

        3.2.3. Changing Regulatory Dynamics 

        3.2.4. Cost Impact

        3.2.5. Regulatory Scenario

    3.3. Market Dynamics

        3.3.1. Drivers

        3.3.2. Restraints

        3.3.3. Opportunity Analysis

4. Market Context

    4.1. Key Industry Developments

    4.2. Disease Epidemiology

    4.3. Regulatory and Reimbursement Scenario

    4.4. Strategic Promotional Strategies by Manufacturer 

5. COVID19 Crisis Impact Analysis

        5.1.1. Current perspectives on the Coronavirus outbreak

        5.1.2. Current GDP Projection and Probable Impact

        5.1.3. Current Economic Projection as compared to 2008 Economic analysis

        5.1.4. COVID19 and Impact Analysis

    5.2. Cancer Diagnostics Market Revenue Impact Analysis

        5.2.1. Historical (pre-COVID), Current (during-COVID), Future (post-COVID)

            5.2.1.1. By Test Type

            5.2.1.2. By Indication

            5.2.1.3. By End User

            5.2.1.4. By Region

        5.2.2. 2020 Market Scenario

    5.3. Impact on Trends Analysis 

    5.4. Recovery Scenario – Short term, Midterm and Long Term Impact

6. Global Cancer Diagnostics Market Value (US$ Mn) Analysis 2016-2020 and Forecast, 2021–2031

    6.1. Historical Market Value (US$ Mn) Analysis, 2016-2020

    6.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031

        6.2.1. Y-o-Y Growth Trend Analysis

        6.2.2. Absolute $ Opportunity Analysis

7. Global Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031, By Test Type

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Mn) Analysis By Test Type, 2016 - 2020

    7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Test Type, 2021 - 2031

        7.3.1. Tumor Biomarkers Tests 

            7.3.1.1. PSA Tests

            7.3.1.2. CTC Tests

            7.3.1.3. AFP Tests

            7.3.1.4. CA Tests

            7.3.1.5. HER2 Tests

            7.3.1.6. BRCA Tests

            7.3.1.7. ALK Tests

            7.3.1.8. CEA Tests

            7.3.1.9. EGFR Mutation Tests

            7.3.1.10. KRAS Mutation Tests

            7.3.1.11. Others

        7.3.2. Imaging

            7.3.2.1. Ultrasound

            7.3.2.2. Mammography

            7.3.2.3. MRI Scan

            7.3.2.4. PET Scan

            7.3.2.5. CT Scan

            7.3.2.6. SPECT & Others

        7.3.3. Biopsy

            7.3.3.1. Needle Biopsy

            7.3.3.2. Endoscopic Biopsy

            7.3.3.3. Bone Marrow Biopsy

            7.3.3.4. Others

        7.3.4. Liquid Biopsy

        7.3.5. Immunohistochemistry

        7.3.6. In Situ Hybridization

    7.4. Market Attractiveness Analysis By Test Type

8. Global Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031, By Indication

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Indication, 2016 - 2020

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2021 - 2031

        8.3.1. Breast Cancer

        8.3.2. Lung Cancer

        8.3.3. Colorectal Cancer

        8.3.4. Melanoma

        8.3.5. Blood Cancer

        8.3.6. Prostate Cancer

        8.3.7. Ovarian Cancer

        8.3.8. Stomach Cancer

        8.3.9. Liver Cancer

        8.3.10. Others 

    8.4. Market Attractiveness Analysis By Indication 

9. Global Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031, By End User

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By End User, 2016 - 2020

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2021 - 2031 

        9.3.1. Hospital Associated Labs

        9.3.2. Independent Diagnostic Laboratories

        9.3.3. Diagnostic Imaging Centers

        9.3.4. Cancer Research Institutes

        9.3.5. Others 

    9.4. Market Attractiveness Analysis By End User

10. Global Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031, by Region

    10.1. Introduction

    10.2. Historical Market Size (US$ Mn) Analysis By Region, 2016 - 2020

    10.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2021-2031

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. East Asia

        10.3.5. South Asia

        10.3.6. Oceania

        10.3.7. Middle East and Africa (MEA)

    10.4. Market Attractiveness Analysis By Region

11. North America Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 - 2020

    11.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2021-2031

        11.3.1. By Country

            11.3.1.1. U.S.

            11.3.1.2. Canada

        11.3.2. By Test Type

        11.3.3. By Indication

        11.3.4. By End User

    11.4. Market Attractiveness Analysis

    11.5. Key Market Participants - Intensity Mapping

    11.6. Drivers and Restraints - Impact Analysis

12. Latin America Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 - 2020

    12.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2021-2031

        12.3.1. By Country

            12.3.1.1. Brazil

            12.3.1.2. Mexico

            12.3.1.3. Argentina

            12.3.1.4. Rest of Latin America

        12.3.2. By Test Type

        12.3.3. By Indication

        12.3.4. By End User

    12.4. Market Attractiveness Analysis

    12.5. Key Market Participants - Intensity Mapping

    12.6. Drivers and Restraints - Impact Analysis

13. Europe Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 - 2020

    13.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2021-2031

        13.3.1. By Country

            13.3.1.1. Germany

            13.3.1.2. Italy

            13.3.1.3. France

            13.3.1.4. U.K.

            13.3.1.5. Spain

            13.3.1.6. BENELUX

            13.3.1.7. Russia

            13.3.1.8. Rest of Europe

        13.3.2. By Test Type

        13.3.3. By Indication

        13.3.4. By End User

    13.4. Market Attractiveness Analysis

    13.5. Key Market Participants - Intensity Mapping

    13.6. Drivers and Restraints - Impact Analysis

14. South Asia Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 - 2020

    14.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2021-2031

        14.3.1. By Country

            14.3.1.1. India

            14.3.1.2. Thailand

            14.3.1.3. Indonesia

            14.3.1.4. Malaysia

            14.3.1.5. Rest of South Asia

        14.3.2. By Test Type

        14.3.3. By Indication

        14.3.4. By End User

    14.4. Market Attractiveness Analysis

    14.5. Key Market Participants - Intensity Mapping

    14.6. Drivers and Restraints - Impact Analysis

15. East Asia Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 - 2020

    15.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2021-2031

        15.3.1. By Country

            15.3.1.1. China

            15.3.1.2. Japan

            15.3.1.3. South Korea

        15.3.2. By Test Type

        15.3.3. By Indication

        15.3.4. By End User

    15.4. Market Attractiveness Analysis

    15.5. Key Market Participants - Intensity Mapping

    15.6. Drivers and Restraints - Impact Analysis

16. Oceania Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 - 2020

    16.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2021-2031

        16.3.1. By Country

            16.3.1.1. Australia

            16.3.1.2. New Zealand

        16.3.2. By Test Type

        16.3.3. By Indication

        16.3.4. By End User

    16.4. Market Attractiveness Analysis

    16.5. Key Market Participants - Intensity Mapping

    16.6. Drivers and Restraints - Impact Analysis

17. Middle East and Africa Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 - 2020

    17.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2021-2031

        17.3.1. By Country

            17.3.1.1. GCC Countries

            17.3.1.2. South Africa

            17.3.1.3. Rest of Middle East and Africa

        17.3.2. By Test Type

        17.3.3. By Indication

        17.3.4. By End User

    17.4. Market Attractiveness Analysis

    17.5. Key Market Participants - Intensity Mapping

    17.6. Drivers and Restraints - Impact Analysis

18. Key and Emerging Countries Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031

    18.1. Introduction

        18.1.1. Market Value Proportion Analysis, By Key Countries

        18.1.2. Global Vs. Country Growth Comparison

    18.2. U.S. Cancer Diagnostics Market Analysis

        18.2.1. By Test Type

        18.2.2. By Indication

        18.2.3. By End User

    18.3. Canada Cancer Diagnostics Market Analysis

        18.3.1. By Test Type

        18.3.2. By Indication

        18.3.3. By End User

    18.4. Mexico Cancer Diagnostics Market Analysis

        18.4.1. By Test Type 

        18.4.2. By Indication

        18.4.3. By End User

    18.5. Brazil Cancer Diagnostics Market Analysis

        18.5.1. By Test Type 

        18.5.2. By Application

        18.5.3. By Indication

        18.5.4. By End User

    18.6. U.K. Cancer Diagnostics Market Analysis

        18.6.1. By Test Type

        18.6.2. By Indication

        18.6.3. By End User

    18.7. Germany Cancer Diagnostics Market Analysis

        18.7.1. By Test Type

        18.7.2. By Indication

        18.7.3. By End User

    18.8. France Cancer Diagnostics Market Analysis

        18.8.1. By Test Type

        18.8.2. By Indication

        18.8.3. By End User

    18.9. Italy Cancer Diagnostics Market Analysis

        18.9.1. By Test Type

        18.9.2. By Indication

        18.9.3. By End User

    18.10. France Cancer Diagnostics Market Analysis

        18.10.1. By Test Type

        18.10.2. By Indication

        18.10.3. By End User

    18.11. Spain Cancer Diagnostics Market Analysis

        18.11.1. By Test Type

        18.11.2. By Indication

        18.11.3. By End User

    18.12. Russia Cancer Diagnostics Market Analysis

        18.12.1. By Test Type

        18.12.2. By Indication

        18.12.3. By End User

    18.13. Poland Cancer Diagnostics Market Analysis

        18.13.1. By Test Type

        18.13.2. By Indication

        18.13.3. By End User

    18.14. China Cancer Diagnostics Market Analysis

        18.14.1. By Test Type

        18.14.2. By Indication

        18.14.3. By End User

    18.15. Japan Cancer Diagnostics Market Analysis

        18.15.1. By Test Type

        18.15.2. By Indication

        18.15.3. By End User

    18.16. South Korea Cancer Diagnostics Market Analysis

        18.16.1. By Test Type

        18.16.2. By Indication

        18.16.3. By End User

    18.17. India Cancer Diagnostics Market Analysis

        18.17.1. By Test Type

        18.17.2. By Indication

        18.17.3. By End User

    18.18. Thailand Cancer Diagnostics Market Analysis

        18.18.1. By Test Type 

        18.18.2. By Indication

        18.18.3. By End User

    18.19. Indonesia Cancer Diagnostics Market Analysis

        18.19.1. By Test Type 

        18.19.2. By Indication

        18.19.3. By End User

    18.20. Malaysia Cancer Diagnostics Market Analysis

        18.20.1. By Test Type 

        18.20.2. By Indication

        18.20.3. By End User

    18.21. Australia Cancer Diagnostics Market Analysis

        18.21.1. By Test Type 

        18.21.2. By Indication

        18.21.3. By End User

    18.22. New Zealand Cancer Diagnostics Market Analysis

        18.22.1. By Test Type 

        18.22.2. By Indication

        18.22.3. By End User

    18.23. GCC Countries Cancer Diagnostics Market Analysis

        18.23.1. By Test Type

        18.23.2. By Indication

        18.23.3. By End User

    18.24. Turkey Cancer Diagnostics Market Analysis

        18.24.1. By Test Type

        18.24.2. By Indication

        18.24.3. By End User

    18.25. South Africa Cancer Diagnostics Market Analysis

        18.25.1. By Test Type

        18.25.2. By Indication

        18.25.3. By End User

19. Market Structure Analysis

    19.1. Market Analysis by Tier of Companies 

    19.2. Market Share Analysis of Top Players

    19.3. Market Concentration

    19.4. Competition Benchmarking

    19.5. Market Presence Analysis

        19.5.1. Regional Footprint by Players

        19.5.2. Product Foot print by Players

        19.5.3. Channel Foot Print by Players

20. Competition Analysis

    20.1. Competition Dashboard

    20.2. Competition Deep Dive (Tentative List)

        20.2.1. Abbott Laboratories

            20.2.1.1. Overview

            20.2.1.2. Product  Portfolio

            20.2.1.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.1.4. Sales Footprint

            20.2.1.5. Strategy Overview

                20.2.1.5.1. Marketing Strategy

                20.2.1.5.2. Product Strategy

                20.2.1.5.3. Channel Strategy

        20.2.2. Roche Holding AG

            20.2.2.1. Overview

            20.2.2.2. Product  Portfolio

            20.2.2.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.2.4. Sales Footprint

            20.2.2.5. Strategy Overview

                20.2.2.5.1. Marketing Strategy

                20.2.2.5.2. Product Strategy

                20.2.2.5.3. Channel Strategy

        20.2.3. Thermo Fisher Scientific Inc. 

            20.2.3.1. Overview

            20.2.3.2. Product  Portfolio

            20.2.3.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.3.4. Sales Footprint

            20.2.3.5. Strategy Overview

                20.2.3.5.1. Marketing Strategy

                20.2.3.5.2. Product Strategy

                20.2.3.5.3. Channel Strategy

        20.2.4. Siemens AG

            20.2.4.1. Overview

            20.2.4.2. Product  Portfolio

            20.2.4.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.4.4. Sales Footprint

            20.2.4.5. Strategy Overview

                20.2.4.5.1. Marketing Strategy

                20.2.4.5.2. Product Strategy

                20.2.4.5.3. Channel Strategy

        20.2.5. Bio Rad Laboratories Inc

            20.2.5.1. Overview

            20.2.5.2. Product  Portfolio

            20.2.5.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.5.4. Sales Footprint

            20.2.5.5. Strategy Overview

                20.2.5.5.1. Marketing Strategy

                20.2.5.5.2. Product Strategy

                20.2.5.5.3. Channel Strategy

        20.2.6. GE Healthcare

            20.2.6.1. Overview

            20.2.6.2. Product  Portfolio

            20.2.6.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.6.4. Sales Footprint

            20.2.6.5. Strategy Overview

                20.2.6.5.1. Marketing Strategy

                20.2.6.5.2. Product Strategy

                20.2.6.5.3. Channel Strategy

        20.2.7. Illumina, Inc

            20.2.7.1. Overview

            20.2.7.2. Product  Portfolio

            20.2.7.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.7.4. Sales Footprint

            20.2.7.5. Strategy Overview

                20.2.7.5.1. Marketing Strategy

                20.2.7.5.2. Product Strategy

                20.2.7.5.3. Channel Strategy

        20.2.8. Koninklijke Philips N.V.

            20.2.8.1. Overview

            20.2.8.2. Product  Portfolio

            20.2.8.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.8.4. Sales Footprint

            20.2.8.5. Strategy Overview

                20.2.8.5.1. Marketing Strategy

                20.2.8.5.2. Product Strategy

                20.2.8.5.3. Channel Strategy

        20.2.9. Toshiba Medical Systems Corporation

            20.2.9.1. Overview

            20.2.9.2. Product  Portfolio

            20.2.9.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.9.4. Sales Footprint

            20.2.9.5. Strategy Overview

                20.2.9.5.1. Marketing Strategy

                20.2.9.5.2. Product Strategy

                20.2.9.5.3. Channel Strategy

        20.2.10. Agilent Technologies, Inc.

            20.2.10.1. Overview

            20.2.10.2. Product  Portfolio

            20.2.10.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.10.4. Sales Footprint

            20.2.10.5. Strategy Overview

                20.2.10.5.1. Marketing Strategy

                20.2.10.5.2. Product Strategy

                20.2.10.5.3. Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Test Type

Table 02: Global Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication

Table 03: Global Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User

Table 04: Global Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Region

Table 05: North America Cancer Diagnostics Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country

Table 06: North America Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type

Table 07: North America Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication

Table 08: North America Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User

Table 09: Latin America Cancer Diagnostics Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country

Table 10: Latin America Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type

Table 11: Latin America Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication

Table 12: Latin America Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User

Table 13: Europe Cancer Diagnostics Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country

Table 14: Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type

Table 15: Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication

Table 16: Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User

Table 17: South Asia Cancer Diagnostics Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country

Table 18: South Asia Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type

Table 19: South Asia Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication

Table 20: South Asia Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User

Table 21: East Asia Cancer Diagnostics Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country

Table 22: East Asia Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type

Table 23: East Asia Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication

Table 24: East Asia Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User

Table 25: Oceania Cancer Diagnostics Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country

Table 26: Oceania Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type

Table 27: Oceania Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication

Table 28: Oceania Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User

Table 29: MEA Cancer Diagnostics Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country

Table 30: MEA Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type

Table 31: MEA Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication

Table 32: MEA Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Cancer Diagnostics Market Value Analysis (US$ Mn), 2016-2020

Figure 02: Global Cancer Diagnostics Market Value Forecast (US$ Mn), 2021-2031

Figure 03: Global Cancer Diagnostics Market Absolute $ Opportunity, 2021 - 2031

Figure 04: Global Cancer Diagnostics Market Share Analysis (%),By Test Type, 2021-2031

Figure 05: Global Cancer Diagnostics Market Y-o-Y Analysis (%), By Test Type, 2021-2031

Figure 06: Global Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2021-2031

Figure 07: Global Cancer Diagnostics Market Share Analysis (%), By Indication, 2021-2031

Figure 08: Global Cancer Diagnostics Market Y-o-Y Analysis (%), By Indication, 2021-2031

Figure 09: Global Cancer Diagnostics Market Attractiveness Analysis By Indication, 2021-2031

Figure 10: Global Cancer Diagnostics Market Share Analysis (%), By End User, 2021-2031

Figure 11: Global Cancer Diagnostics Market Y-o-Y Analysis (%), By End User, 2021-2031

Figure 12: Global Cancer Diagnostics Market Attractiveness Analysis by End User, 2021-2031

Figure 13: Global Cancer Diagnostics Market Share Analysis (%), By Region, 2021-2031

Figure 14: Global Cancer Diagnostics Market Y-o-Y Analysis (%), By Region, 2021-2031

Figure 15: Global Cancer Diagnostics Market Attractiveness Analysis by Region, 2021-2031

Figure 16: North America Cancer Diagnostics Market Value Share, By Test Type, 2020 (E)

Figure 17: North America Cancer Diagnostics Market Value Share, By Indication, 2020 (E)

Figure 18: North America Cancer Diagnostics Market Value Share, By End User, 2020 (E)

Figure 19: North America Cancer Diagnostics Market Value Share, By Country, 2020 (E)

Figure 20: North America Cancer Diagnostics Market Value Analysis (US$ Mn), 2016-2020

Figure 21: North America Cancer Diagnostics Market Value Forecast (US$ Mn), 2021-2031

Figure 22: North America Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2021-2031

Figure 23: North America Cancer Diagnostics Market Attractiveness Analysis By Indication, 2021-2031

Figure 24: North America Cancer Diagnostics Market Attractiveness Analysis by End User, 2021-2031

Figure 25: North America Cancer Diagnostics Market Attractiveness Analysis by Country, 2021-2031

Figure 26: Latin America Cancer Diagnostics Market Value Share, By Test Type, 2020 (E)

Figure 27: Latin America Cancer Diagnostics Market Value Share, By Indication, 2020 (E)

Figure 28: Latin America Cancer Diagnostics Market Value Share, By End User, 2020 (E)

Figure 29: Latin America Cancer Diagnostics Market Value Share, By Country, 2020 (E)

Figure 30: Latin America Cancer Diagnostics Market Value Analysis (US$ Mn), 2016-2020

Figure 31: Latin America Cancer Diagnostics Market Value Forecast (US$ Mn), 2021-2031

Figure 32: Latin America Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2021-2031

Figure 33: Latin America Cancer Diagnostics Market Attractiveness Analysis By Indication, 2021-2031

Figure 34: Latin America Cancer Diagnostics Market Attractiveness Analysis by End User, 2021-2031

Figure 35: Latin America Cancer Diagnostics Market Attractiveness Analysis by Country, 2021-2031

Figure 36: Europe Cancer Diagnostics Market Value Share, By Test Type, 2020 (E)

Figure 37: Europe Cancer Diagnostics Market Value Share, By Indication, 2020 (E)

Figure 38: Europe Cancer Diagnostics Market Value Share, By End User, 2020 (E)

Figure 39: Europe Cancer Diagnostics Market Value Share, By Country, 2020 (E)

Figure 40: Europe Cancer Diagnostics Market Value Analysis (US$ Mn), 2016-2020

Figure 41: Europe Cancer Diagnostics Market Value Forecast (US$ Mn), 2021-2031

Figure 42: Europe Cancer Diagnostics Market Attractiveness Analysis By Test Type , 2021-2031

Figure 43: Europe Cancer Diagnostics Market Attractiveness Analysis By Indication, 2021-2031

Figure 44: Europe Cancer Diagnostics Market Attractiveness Analysis by End User, 2021-2031

Figure 45: Europe Cancer Diagnostics Market Attractiveness Analysis by Country, 2021-2031

Figure 46: South Asia Cancer Diagnostics Market Value Share, By Test Type, 2020 (E)

Figure 47: South Asia Cancer Diagnostics Market Value Share, By Indication, 2020 (E)

Figure 48: South Asia Cancer Diagnostics Market Value Share, By End User, 2020 (E)

Figure 49: South Asia Cancer Diagnostics Market Value Share, By Country, 2020 (E)

Figure 50: South Asia Cancer Diagnostics Market Value Analysis (US$ Mn), 2016-2020

Figure 51: South Asia Cancer Diagnostics Market Value Forecast (US$ Mn), 2021-2031

Figure 52: South Asia Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2021-2031

Figure 53: South Asia Cancer Diagnostics Market Attractiveness Analysis By Indication, 2021-2031

Figure 54: South Asia Cancer Diagnostics Market Attractiveness Analysis by End User, 2021-2031

Figure 55: South Asia Cancer Diagnostics Market Attractiveness Analysis by Country, 2021-2031

Figure 56: East Asia Cancer Diagnostics Market Value Share, By Test Type, 2020 (E)

Figure 57: East Asia Cancer Diagnostics Market Value Share, By Indication, 2020 (E)

Figure 58: East Asia Cancer Diagnostics Market Value Share, By End User, 2020 (E)

Figure 59: East Asia Cancer Diagnostics Market Value Share, By Country, 2020 (E)

Figure 60: East Asia Cancer Diagnostics Market Value Analysis (US$ Mn), 2016-2020

Figure 61: East Asia Cancer Diagnostics Market Value Forecast (US$ Mn), 2021-2031

Figure 62: East Asia Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2021-2031

Figure 63: East Asia Cancer Diagnostics Market Attractiveness Analysis By Indication, 2021-2031

Figure 64: East Asia Cancer Diagnostics Market Attractiveness Analysis by End User, 2021-2031

Figure 65: East Asia Cancer Diagnostics Market Attractiveness Analysis by Country, 2021-2031

Figure 66: Oceania Cancer Diagnostics Market Value Share, By Test Type, 2020 (E)

Figure 67: Oceania Cancer Diagnostics Market Value Share, By Indication, 2020 (E)

Figure 68: Oceania Cancer Diagnostics Market Value Share, By End User, 2020 (E)

Figure 69: Oceania Cancer Diagnostics Market Value Share, By Country, 2020 (E)

Figure 70: Oceania Cancer Diagnostics Market Value Analysis (US$ Mn), 2016-2020

Figure 71: Oceania Cancer Diagnostics Market Value Forecast (US$ Mn), 2021-2031

Figure 72: Oceania Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2021-2031

Figure 73: Oceania Cancer Diagnostics Market Attractiveness Analysis By Indication, 2021-2031

Figure 74: Oceania Cancer Diagnostics Market Attractiveness Analysis by End User, 2021-2031

Figure 75: Oceania Cancer Diagnostics Market Attractiveness Analysis by Country, 2021-2031

Figure 76: MEA Cancer Diagnostics Market Value Share, By Test Type, 2020 (E)

Figure 77: MEA Cancer Diagnostics Market Value Share, By Indication, 2020 (E)

Figure 78: MEA Cancer Diagnostics Market Value Share, By End User, 2020 (E)

Figure 79: MEA Cancer Diagnostics Market Value Share, By Country, 2020 (E)

Figure 80: MEA Cancer Diagnostics Market Value Analysis (US$ Mn), 2016-2020

Figure 81: MEA Cancer Diagnostics Market Value Forecast (US$ Mn), 2021-2031

Figure 82: MEA Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2021-2031

Figure 83: MEA Cancer Diagnostics Market Attractiveness Analysis By Indication, 2021-2031

Figure 84: MEA Cancer Diagnostics Market Attractiveness Analysis by End User, 2021-2031

Figure 85: MEA Cancer Diagnostics Market Attractiveness Analysis by Country, 2021-2031

Figure 86: U.S. Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 87: U.S. Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 88: U.S. Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 89: North America Vs. U.S. Growth Comparison

Figure 90: Canada Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 91: Canada Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 92: Canada Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 93: North America Vs. Canada Growth Comparison

Figure 94: Brazil Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 95: Brazil Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 96: Brazil Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 97: Latin America Vs. Brazil Growth Comparison

Figure 98: Mexico Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 99: Mexico Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 100: Mexico Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 101: Latin America Vs. Mexico Growth Comparison

Figure 102: Argentina Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 103: Argentina Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 104: Argentina Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 105: Latin America Vs. Argentina Growth Comparison

Figure 106: U.K. Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 107: U.K. Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 108: U.K. Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 109: Europe Vs. U.K. Growth Comparison

Figure 110: Germany Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 111: Germany Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 112: Germany Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 113: Europe Vs. Germany Growth Comparison

Figure 114: Italy Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 115: Italy Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 116: Italy Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 117: Europe Vs. Italy Growth Comparison

Figure 118: France Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 119: France Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 120: France Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 121: Europe Vs. France Growth Comparison

Figure 122: Spain Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 123: Spain Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 124: Spain Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 125: Europe Vs. Spain Growth Comparison

Figure 126: Russia Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 127: Russia Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 128: Russia Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 129: Europe Vs. Russia Growth Comparison

Figure 130: India Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 131: India Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 132: India Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 133: South Asia Vs. India Growth Comparison

Figure 134: Thailand Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 135: Thailand Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 136: Thailand Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 137: South Asia Vs. Thailand Growth Comparison

Figure 138: Malaysia Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 139: Malaysia Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 140: Malaysia Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 141: South Asia Vs. Malaysia Growth Comparison

Figure 142: Indonesia Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 143: Indonesia Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 144: Indonesia Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 145: South Asia Vs. Indonesia Growth Comparison

Figure 146: China Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 147: China Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 148: China Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 149: East Asia Vs. China Growth Comparison

Figure 150: Japan Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 151: Japan Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 152: Japan Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 153: East Asia Vs. Japan Growth Comparison

Figure 154: South Korea Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 155: South Korea Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 156: South Korea Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 157: East Asia Vs. South Korea Growth Comparison

Figure 158: Australia Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 159: Australia Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 160: Australia Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 161: Oceania Vs. Australia Growth Comparison

Figure 162: New Zealand Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 163: New Zealand Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 164: New Zealand Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 165: Oceania Vs. New Zealand Growth Comparison

Figure 166: Turkey Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 167: Turkey Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 168: Turkey Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 169: MEA Vs. Turkey Growth Comparison

Figure 170: GCC Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 171: GCC Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 172: GCC Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 173: MEA Vs. GCC Growth Comparison

Figure 174: South Africa Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031

Figure 175: South Africa Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031

Figure 176: South Africa Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031

Figure 177: MEA Vs. South Africa Growth Comparison

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Cancer Antigens Market

Published : October 2019

Healthcare

Colorectal Cancer Molecular Diagnostics Market

Published : January 2019

Healthcare

Cancer Biological Therapy Market

Published : November 2016

Healthcare

Molecular Diagnostics Market

Published : February 2016

Google translate

Cancer Diagnostics Market